The hemophagocytic syndrome (HPS) is a clinicopathological entity characterized by macrophage or histiocyte activation and marked hemophagocytosis in bone marrow (BM) and other parts of the reticuloendothelial system, resulting in cytopenias. 1 Primary or familial HPS is genetically mediated and usually occurs in childhood. 2 Secondary or reactive HPS (R-HPS) is associated with infections, malignancies and autoimmune disorders. 3 We describe a case of R-HPS with life-threatening gastrointestinal (GI) tract bleeding after autologous peripheral stem cell transplantation (APSCT) for multiple myeloma (MM), which resolved after high-dose intravenous immunoglobulin (IVIG) therapy.
In May 2005, a 54-year-old woman with MM stage III A entered complete remission (CR) after four cycles of vincristine, doxorubicin and dexamethasone combination therapy. Autologous peripheral stem cell transplantation conditioning included melphalan 140 mg/m 2 . The graft consisted of 2 Â 10 6 CD34 þ cells/kg. G-CSF 10 mg/kg was started on D0. She was prescribed cefepime and vancomycin on D þ 4, and amphotericin B on D þ 7, for fever of unknown origin. These treatments were withdrawn after neutrophil recovery on D þ 10. During the aplastic phase, she received two packs of red blood cells (RBC) and four transfusions of irradiated, filtered platelets (PLT). On D þ 12, her hemoglobin level was 11.6 g/dl, the hematocrit 33%, the white blood cell count 9100/ml (absolute neutrophil count 5915/ml) and the PLT count 15 000/ml, and G-CSF was withdrawn. Four days later, her thrombocytopenia and anemia worsened (PLT 3000/ml, hemoglobin 8.7 g/dl and hematocrit 27%) and she developed fever (391C), splenomegaly and disseminated petechiae. The results of clotting tests were normal, except for fibrinogen of 1 g/l. No infection was detected by urine and blood culture and computed tomography of the chest, abdomen and sinuses. Cefepime, vancomycin and amphotericin B were re-introduced but fever persisted. Over the following 3 days, she developed hypovolemic shock due to massive GI tract bleeding. Gastroscopy showed diffuse petechiae and mucosal bleeding. A BM aspirate contained 3% histiocytes showing hemophagocytic activity. Reactive HPS was diagnosed. Red blood cells and PLT were transfused on average four times a day, but failed to increase the corresponding cell counts. Thorough investigation failed to detect bacterial, fungal, parasitic or viral (HSV, EBV, HIV and CMV) infection, an autoimmune disorder, or a malignancy. At this time, she was receiving aciclovir prophylaxis and was still in CR from MM. On D þ 21, she was prescribed IVIG 1 g/kg/day for 2 days and dexamethasone 40 mg/day for 4 days. The bleeding stopped and the PLT count rose to 129 000/ml. However, on D þ 30, her PLT count again fell (24 000/ml) and BM aspiration showed persistent hemophagocytosis with 4% histiocytes. Further courses of IVIG were given once a week for 2 weeks and the PLT count stabilized. A BM aspirate obtained on D þ 39 was normal, with no evidence of hemophagocytosis. Reactive HPS did not recur.
Hemophagocytic syndrome is diagnosed by means of BM studies showing benign histiocytes actively phagocytosing hematopoietic stem cells. 1 The prognosis is poor, with an overall mortality rate of 15-60% despite prompt aggressive treatment. 1, 3, 4 The pathogenesis of HPS is not fully understood. One proposed mechanism is uncontrolled T-lymphocyte and macrophage activation leading to massive cytokine release and abnormal immune responses resulting in widespread hemophagocytosis. 5, 6 Direct evidence of massive infiltration by macrophages and IFN-g-producing cytotoxic T cells showing active hemophagocytosis and tumor necrosis factor (TNF)-a and IL-6 release in the liver of children with HPS was recently reported. 7 We found no evidence of potential infectious, autoimmune or malignant triggers of R-HPS in our patient, despite extensive investigations. She was in CR from MM and close to hematological recovery when HPS occurred.
Peripheral blood stem cell grafts contain more immune effectors (lymphocytes and monocytes) with higher cytokine expression than do BM grafts, but their impact on the recipient's immune function after transplantation is unclear. 10 This may be involved in the pathogenesis of HPS after APSCT. 8 There are no reports of HPS related to the use of G-CSF or GM-CSF.
Early treatment initiation is mandatory in HPS. Options include specific treatment of the underlying disorder in patients with a known cause, high-dose steroids, cytostatic drugs such as etoposide and cyclosporine A, plasmapheresis and TNF-a antagonists, but no randomized trials have been published. 9 High-dose IVIG has been successfully used mainly in virus-associated HPS. 6 Intravenous immunoglobulin induces phagocyte Fc receptor blockade and may downregulate immunoglobulin synthesis and immune stimulation. 10 This may reduce the immunological response and prevent the excessive cytokine release involved in HPS.
In the present case, PLT were the cell lineage most strongly affected, resulting in a life-threatening hemorrhagic syndrome. The immunomodulatory effect of IVIG was reflected by the hematological improvement and the arrest of GI tract bleeding.
Although dexamethasone co-administration might have contributed to the patient's recovery, it is noteworthy that HPS recurred during dexamethasone treatment and that the syndrome was only controlled when IVIG was reintroduced.
To our knowledge, this is the first reported case of R-HPS after APSCT. It appeared to be triggered by immunological recovery and excessive cytokine release. Intravenous immunoglobulin appeared to be effective, and its known mechanism of action is compatible with the presumed pathophysiology of HPS. Early IVIG treatment of this patient's life-threatening HPS led to rapid recovery and a favorable long-term outcome.
